Merck KGaA (MRK) Given a €82.00 Price Target by Barclays Analysts
Barclays set a €82.00 ($95.35) target price on Merck KGaA (FRA:MRK) in a report published on Tuesday, Borsen Zeitung reports. The brokerage currently has a sell rating on the healthcare company’s stock.
Other research analysts have also issued reports about the stock. Sanford C. Bernstein set a €105.00 ($122.09) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Tuesday, February 5th. Kepler Capital Markets set a €108.00 ($125.58) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Thursday, January 24th. UBS Group set a €115.00 ($133.72) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Thursday, March 7th. Finally, Credit Suisse Group set a €110.00 ($127.91) target price on shares of Merck KGaA and gave the stock a buy rating in a research note on Friday, March 8th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and five have given a buy rating to the stock. Merck KGaA currently has a consensus rating of Hold and a consensus price target of €101.05 ($117.50).
Shares of Merck KGaA stock opened at €91.84 ($106.79) on Tuesday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: How interest rates affect municipal bond prices
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.